Back to Search
Start Over
Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC.
- Source :
-
Targeted oncology [Target Oncol] 2015 Jun; Vol. 10 (2), pp. 247-53. Date of Electronic Publication: 2014 Aug 15. - Publication Year :
- 2015
-
Abstract
- All lung cancer patients with mutant epidermal growth factor receptor (EGFR) or rearranged EML4-ALK eventually develop acquired resistance to treatment. Rebiopsy may give insight into the resistance mechanisms and direct further lines of treatment. Here, we evaluate the potential interest and limitations of rebiopsy. Patients with mutant EGFR or rearranged EML4-ALK non-small cell lung cancer (NSCLC) and acquired resistance to tyrosine kinase inhibitors were included in a retrospective study to determine the percentage of patients who underwent rebiopsy and whether rebiopsy would have been possible, or not, in the remaining patients. In a cohort of 84 patients from 6 institutions, a biopsy had been performed in 39 cases. Biopsy samples were sufficient for histopathological or cytological examination in 35 cases (89.7 %). Complete or partial response had been observed in 84.5 % of patients whose cancer further progressed and who underwent rebiopsy. A biopsy could have been considered in 30 of the 45 remaining patients. Those with brain (N = 9) and bone (N = 2) metastases and/or with contraindications (N = 6) were excluded (two patients had both brain metastases and a contraindication). The rebiopsy target was thoracic in 62 % of cases and on distant metastases in 38 % of cases. Patients with NSCLC and an activating mutation could undergo a rebiopsy in 72 % of cases. A response to treatment does not preclude the possibility of rebiopsy at the time of progression.
- Subjects :
- Adult
Aged
Aged, 80 and over
Biomarkers, Tumor metabolism
Biopsy
Carcinoma, Non-Small-Cell Lung enzymology
Carcinoma, Non-Small-Cell Lung genetics
Carcinoma, Non-Small-Cell Lung secondary
Disease Progression
Drug Resistance, Neoplasm
ErbB Receptors metabolism
Female
France
Gene Rearrangement
Humans
Lung Neoplasms enzymology
Lung Neoplasms genetics
Lung Neoplasms pathology
Male
Middle Aged
Molecular Diagnostic Techniques
Mutation
Oncogene Proteins, Fusion
Predictive Value of Tests
Retrospective Studies
Signal Transduction drug effects
Time Factors
Treatment Outcome
Antineoplastic Agents therapeutic use
Biomarkers, Tumor antagonists & inhibitors
Biomarkers, Tumor genetics
Carcinoma, Non-Small-Cell Lung drug therapy
ErbB Receptors antagonists & inhibitors
ErbB Receptors genetics
Lung Neoplasms drug therapy
Oncogenes
Protein Kinase Inhibitors therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1776-260X
- Volume :
- 10
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Targeted oncology
- Publication Type :
- Academic Journal
- Accession number :
- 25119973
- Full Text :
- https://doi.org/10.1007/s11523-014-0332-y